These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 30976993)

  • 1. Induction and Impact of Anti-Drug Responses Elicited by a Human Recombinant Coagulation Factor FXa
    Parng C; Bolt M; Pittman DD; Caiazzo T; Dyleski L; Gorovits B; Webster R
    AAPS J; 2019 Apr; 21(3):52. PubMed ID: 30976993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 1 dose-escalating study to evaluate the safety, pharmacokinetics, and pharmacodynamics of a recombinant factor Xa variant (FXa
    Parsons-Rich D; Hua F; Li G; Kantaridis C; Pittman DD; Arkin S
    J Thromb Haemost; 2017 May; 15(5):931-937. PubMed ID: 28294526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical Pharmacokinetics, Pharmacodynamics, Tissue Distribution, and Interspecies Scaling of Recombinant Human Coagulation Factor Xa
    Parng C; Markiewicz V; Chen J; Leary B; Duriga N; Dyleski L; Caiazzo T; Bolt M; Joyce A; Gorovits B; Pittman DD; Webster R
    J Pharm Sci; 2017 Aug; 106(8):2136-2143. PubMed ID: 28389265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correction of human hemophilia A whole blood abnormalities with a novel bypass agent: zymogen-like FXa(I16L).
    George LA; Thalji NK; Raffini LJ; Gimotty PA; Camire RM
    J Thromb Haemost; 2015 Sep; 13(9):1694-8. PubMed ID: 26190406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A zymogen-like factor Xa variant corrects the coagulation defect in hemophilia.
    Ivanciu L; Toso R; Margaritis P; Pavani G; Kim H; Schlachterman A; Liu JH; Clerin V; Pittman DD; Rose-Miranda R; Shields KM; Erbe DV; Tobin JF; Arruda VR; Camire RM
    Nat Biotechnol; 2011 Oct; 29(11):1028-33. PubMed ID: 22020385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hemostatic agents of broad applicability produced by selective tuning of factor Xa zymogenicity.
    Ivanciu L; Camire RM
    Blood; 2015 Jul; 126(1):94-102. PubMed ID: 25896653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A rapid pro-hemostatic approach to overcome direct oral anticoagulants.
    Thalji NK; Ivanciu L; Davidson R; Gimotty PA; Krishnaswamy S; Camire RM
    Nat Med; 2016 Aug; 22(8):924-32. PubMed ID: 27455511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay.
    Barrett YC; Wang Z; Frost C; Shenker A
    Thromb Haemost; 2010 Dec; 104(6):1263-71. PubMed ID: 20978714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and pharmacodynamics of rFVIIa and new improved bypassing agents for the treatment of haemophilia.
    Agersø H; Tranholm M
    Haemophilia; 2012 Jul; 18 Suppl 5():6-10. PubMed ID: 22757678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of biomarkers for monitoring thrombogenic potential of FXaI16L.
    Bolt MW; Hua F; Brenneman KA; Graves JE; Arkin S; Criswell K
    Blood Coagul Fibrinolysis; 2020 Jan; 31(1):16-28. PubMed ID: 31687988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of a novel selective factor Xa inhibitor, DJT06001, which reduces thrombus formation with low risk of bleeding.
    Hu X; Xiao Y; Yu C; Zuo Y; Yang W; Wang X; Gu B; Li J
    Eur J Pharmacol; 2018 Apr; 825():85-91. PubMed ID: 29475063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone.
    Tomokiyo K; Nakatomi Y; Araki T; Teshima K; Nakano H; Nakagaki T; Miyamoto S; Funatsu A; Iwanaga S
    Vox Sang; 2003 Nov; 85(4):290-9. PubMed ID: 14633255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences between human and rabbit coagulation factor X-implications for in vivo models of thrombosis.
    Edwards ST; Betz A; James HL; Thompson E; Yonkovich SJ; Sinha U
    Thromb Res; 2002 Apr; 106(1):71-9. PubMed ID: 12165292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical efficacy and safety of rVIII-SingleChain (CSL627), a novel recombinant single-chain factor VIII.
    Zollner SB; Raquet E; Müller-Cohrs J; Metzner HJ; Weimer T; Pragst I; Dickneite G; Schulte S
    Thromb Res; 2013 Aug; 132(2):280-7. PubMed ID: 23830969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation.
    Warkentin TE; Greinacher A; Craven S; Dewar L; Sheppard JA; Ofosu FA
    Thromb Haemost; 2005 Nov; 94(5):958-64. PubMed ID: 16363236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Edoxaban: Impact on routine and specific coagulation assays. A practical laboratory guide.
    Douxfils J; Chatelain B; Chatelain C; Dogné JM; Mullier F
    Thromb Haemost; 2016 Jan; 115(2):368-81. PubMed ID: 26510969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Species differences in anticoagulant and anti-Xa activity of DX-9065a, a highly selective factor Xa inhibitor.
    Hara T; Yokoyama A; Morishima Y; Kunitada S
    Thromb Res; 1995 Oct; 80(1):99-104. PubMed ID: 8578544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antithrombotic and anticoagulant profiles of TAK-442, a novel factor Xa inhibitor, in a rabbit model of venous thrombosis.
    Kawamura M; Konishi N; Hiroe K; Shofuda K; Imaeda Y; Fujimoto T; Kubo K
    J Cardiovasc Pharmacol; 2010 Aug; 56(2):156-61. PubMed ID: 20410831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical pharmacokinetics of a novel anti-c-Met antibody-drug conjugate, SHR-A1403, in rodents and non-human primates.
    Yang C; Zhao X; Sun X; Li J; Wang W; Zhang L; Gou S
    Xenobiotica; 2019 Sep; 49(9):1097-1105. PubMed ID: 30299189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
    Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
    Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.